View Cart  

FDA Lacks Policy to Deal With EU Falsified Medicines Directive, Shortage Concern Looms

The FDA’s lack of a policy or guidance to help API manufacturers deal with a new European directive is causing concern among manufacturers about lost sales and drug shortages in Europe, an expert says.

To View This Article:


Subscribe To Drug Industry Daily